Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Anti-GPIIb/IIIa drugs: Current strategies and future directions
Autore:
Coller, BS;
Indirizzi:
CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA CUNY Mt Sinai Sch Med New York NY USA 10029 t Med, New York, NY 10029 USA
Titolo Testata:
THROMBOSIS AND HAEMOSTASIS
fascicolo: 1, volume: 86, anno: 2001,
pagine: 427 - 443
SICI:
0340-6245(200107)86:1<427:ADCSAF>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLATELET GLYCOPROTEIN-IIB/IIIA; ACUTE CORONARY SYNDROMES; ACUTE MYOCARDIAL-INFARCTION; C7E3 FAB ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONISTS; ACUTE PROFOUND THROMBOCYTOPENIA; UNSTABLE ANGINA-PECTORIS; ST-SEGMENT ELEVATION; GP IIB-IIIA; THROMBIN GENERATION;
Keywords:
abciximab; tirofiban; eptifibatide; angioplasty; unstable angina; antithrombotic therapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
149
Recensione:
Indirizzi per estratti:
Indirizzo: Coller, BS CUNY Mt Sinai Sch Med, Dept Med, 1 Gustave L Levy Pl, New York,NY 10029 USA CUNY Mt Sinai Sch Med 1 Gustave L Levy Pl New York NY USA 10029
Citazione:
B.S. Coller, "Anti-GPIIb/IIIa drugs: Current strategies and future directions", THROMB HAEM, 86(1), 2001, pp. 427-443

Abstract

Three platelet glycoprotein (GP) IIb/lIIa receptor antagonists have been approved as adjunctive therapy to decrease the ischemic complications of percutaneous coronary interventions (PCI) and/or unstable angina. They includethe chimeric murine/human monoclonal antibody 7E3 Fab fragment (abciximab), a cyclic heptapeptide based on the KGD amino acid sequence (eptifibatide), and a nonpeptide mimetic of the RGD sequence (tirofiban). The agents are very effective in providing both short-term and long-term benefit after PCI, and one agent has also demonstrated a progressive long-term mortality benefit. The long-term mortality benefit is highly cost-effective when compared to other medical interventions. The benefits in treating unstable angina without PCI are less dramatic and robust, with some agents providing no benefit. Severe thrombocytopenia is an infrequent, but potentially serious, complication of therapy with all of the agents. The risk of major bleeding isincreased only minimally or not at all by the drugs. Currently, a number of new indications for GPIIb/IIIa antagonists are under study, including acute myocardial infarction (+/- thrombolytic therapy, +/- PCI) and stroke. Inaddition to their impact on improving outcome, the results of clinical trials with these agents provide crucial insights into the contribution of GPIIb/IIIa-mediated platelet function in the pathophysiology of thrombotic vascular disease.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/11/20 alle ore 00:35:39